Postural Control in Chronic Obstructive Pulmonary Disease (NEUROTIGUE P)

Influence of Cognitive Load on Postural Control in People With Chronic Obstructive Pulmonary Disease

Postural control impairment is common in people with COPD (pwCOPD), which can increase the risk of falls and affect quality of life. However, the majority of existing studies examine this postural control in isolation, without taking into account the cognitive demands that occur during activities of daily living during which individuals are often required to perform a mental task while maintaining their balance. This research aims to fill this gap by studying how a cognitive task can influence postural control in pwCOPD. We hypothesized an impaired postural control in pwCOPD compared to healthy individuals, which would be exacerbated in presence of a cognitive task.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease (COPD)
• Intervention / Treatment: Other: Evaluation of cognitive task on static balance; Other: Evaluation of visual feedback on static balance

Detailed Description

This observational study is based on the analyses of data (center of pressure displacement) recorded during the first visit of NEUROTIGUE study (NCT04028973).

Center of pressure (COP) displacement were recorded during 60s of static balance in four conditions (random order) :

• Eyes open without cognitive task
• Eyes open with cognitive task
• Eyes closed without cognitive task
• Eyes closed with cognitive task The cognitive task used was a working memory task : the 1-back task. COP displacement will be assess using a conjunction of parameters to provide a comprehensive understanding of postural control (e.g., amplitude, standard deviation, non-linear approaches).

• Study Type: Observational
• Enrollment (Actual): 36

Contacts and Locations

Study Locations

• France
  • VAR
    • Toulon, VAR, France, 83100
      • Université de Toulon - Laboratoire J-AP2S

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Participants enrolled in NEUROTIGUE study (NCT04028973)

Description

Inclusion Criteria:

COPD patients :

• GOLD II - III or IV
• FEV1 <80% of predicted values
• Men and women aged 40 years and over
• French-speaking participant
• BMI <30 kg / m²
• Stable condition (i.e. without exacerbation) for more than 15 days
• Able to express their consent in writing prior to any participation in the study
• Affiliates or beneficiaries of a social security
• Minimum score of 26 on the MMSE questionnaire of 3 months or less

Healthy volunteers :

• Men and women aged 40 years and over
• French-speaking participant
• BMI <30 kg / m²
• No known chronic respiratory, cardiovascular, metabolic, renal or neuromuscular pathologies
• Able to express their consent in writing prior to any participation in the study
• Affiliates or beneficiaries of a social security
• Minimum score of 26 on the MMSE questionnaire of 3 months or less

For all participants :

-Subject who has not objected to the reuse of data collected

Exclusion Criteria:

• COPD patients :
• Alcoholism, i.e. > 21 glasses a week for men and >14 glasses a week for women
• Psychiatric pathologies or antecedent of behavioral disorders
• Patients treated with oral or systemic corticosteroids (> 0.5 mg / kg / day for > 7 days)
• Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries)
• Severe vision or hearing problems not corrected
• Patient oxygen dependent
• Patients in exclusion period from another research protocol
• Pregnant women (known pregnancy) or lactating women
• Patient deprived of liberty by a judicial or administrative decision
• Patient subject to a legal protection measure or unable to express their consent
• Patient who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study
• Patient unable to follow study procedures and to respect visits throughout the study period
• Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study
• Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study
• Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study

Healthy volunteers:

• Alcoholism, i.e. > 21 glasses a week for men and >14 glasses a week for women
• Psychiatric pathologies or antecedent of behavioral disorders
• Patients treated with oral or systemic corticosteroids (> 0.5 mg / kg / day for > 7 days)
• Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries)
• Severe vision or hearing problems not corrected
• Subjects in exclusion period from another research protocol
• Pregnant women (known pregnancy) or lactating women
• Regular physical activity with a frequency greater than 3 sessions per week
• Participant deprived of liberty by a judicial or administrative decision
• Participant subject to a legal protection measure or unable to express their consent
• Participant who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study
• Participant unable to follow study procedures and to respect visits throughout the study period
• Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study
• Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study
• Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with COPD; Patients with chronic obstructive pulmonary disease	Other: Evaluation of cognitive task on static balance; Static balance with and without cognitive task (i.e., 1-back task); Other: Evaluation of visual feedback on static balance; Static balance with and without visual feedback (i.e., eyes closed and open).
Control participants; Healthy individuals	Other: Evaluation of cognitive task on static balance; Static balance with and without cognitive task (i.e., 1-back task); Other: Evaluation of visual feedback on static balance; Static balance with and without visual feedback (i.e., eyes closed and open).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of the range of COP displacement between groups and experimental conditions	Range of COP displacement correspond to the maximal amplitude of the path of COP in anteroposterior and mediolateral directions.	10 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of Sample Entropy (SampEn) of COP displacement between groups and experimental conditions	SampEn is a non-linear approach allowing to quantify the regularity of COP displacement in anteroposterior and mediolateral directions.	10 minutes
Difference of total COP displacement between groups and experimental conditions	The total COP displacement corresponds to the total distance covered by the COP during a recording period.	10 minutes
Difference of area of COP displacement between groups and experimental conditions	Area of COP displacement represents the area covered by COP during a recording period.	10 minutes

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of mean COP position between groups and experimental conditions	Difference of mean COP position between groups and experimental conditions	10 minutes
Difference of the mean speed of COP displacement between groups and experimental conditions	Difference of the mean speed of COP displacement between groups and experimental conditions	10 minutes

Collaborators and Investigators

• Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
• Collaborators: Université de Toulon
• Investigators: Study Director: Jean-Marc Vallier, MD, PHD, Université de Toulon

Study record dates

Study Major Dates

• Study Start (Actual): March 7, 2025
• Primary Completion (Actual): March 8, 2025
• Study Completion (Actual): March 8, 2025

Study Registration Dates

• First Submitted: March 3, 2025
• First Submitted That Met QC Criteria: March 3, 2025
• First Posted (Actual): March 7, 2025

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 10, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: COPD; Postural control; Variability; Static balance; Cognitive task; Non-linear
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 2025-CHITS-006

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No